— Research monograph
BPC-157 + TB-500 (Wolverine)
A co-formulation of two repair-pathway peptides in a single lyophilized vial.
- Class
- Pentadecapeptide (BPC-157) + Thymosin Beta-4 fragment (TB-500) co-formulation
- Half-life (research)
- BPC-157: ~4 hr (preclinical, rat). TB-500: not well-characterized in the public literature.
- Origin
- BPC-157 was first characterized at the University of Zagreb by the Sikiric laboratory in the early 1990s as a stable fragment of body protection compound, a polypeptide identified in gastric juice. Thymosin Beta-4 (the parent peptide of TB-500) was originally isolated from bovine thymus by Allan Goldstein in 1981.
- Solubility
- Both peptides reconstitute readily in bacteriostatic water at 2–5 mg/mL.
What is BPC-157 + TB-500 (Wolverine)?
BPC-157 is a synthetic pentadecapeptide consisting of fifteen amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a fragment of body protection compound, a polypeptide originally identified in human gastric juice. It is notable in the peptide literature for unusually high stability in acidic environments — a property that has made it a frequent subject of preclinical investigation.
TB-500 is a synthetic acetylated 17-amino-acid fragment of Thymosin Beta-4 (Tβ4), a 43-amino-acid peptide naturally expressed in most mammalian tissues. The fragment corresponds to the active actin-binding region of the parent peptide.
The Wolverine co-formulation places both peptides in a single lyophilized vial at 10 mg each. Researchers requesting this blend most commonly cite combined-pathway repair studies as their rationale for the pairing.
How does BPC-157 + TB-500 (Wolverine) work?
BPC-157 has been investigated in preclinical models for effects on angiogenesis (VEGF/VEGFR2 axis modulation), nitric oxide system regulation, growth hormone receptor expression, and dopaminergic / serotonergic system interactions. TB-500 functions primarily as an actin-sequestering protein involved in cell motility, organogenesis, and the regulation of actin polymerization in research models. Both peptides remain under active investigation; mechanisms described above reflect preclinical findings, not clinical conclusions.
Research applications
- Tissue-repair pathway investigation
- Tendon and ligament healing models
- Vascular angiogenesis research
- GI mucosal integrity studies
- Actin cytoskeleton dynamics
Handling & reconstitution
BPC-157 + TB-500 (Wolverine) ships as a sealed, lyophilized (freeze-dried) powder and is reconstituted with bacteriostatic water for laboratory handling. Both peptides reconstitute readily in bacteriostatic water at 2–5 mg/mL. Concentration equals vial mass divided by diluent volume.
See the BPC-157 + TB-500 blend reconstitution protocol for a step-by-step guide and an interactive research calculator (vial size → diluent → draw volume).
Frequently asked questions
What is BPC-157 + TB-500 (Wolverine)?
BPC-157 is a synthetic pentadecapeptide consisting of fifteen amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a fragment of body protection compound, a polypeptide originally identified in human gastric juice. It is notable in the peptide literature for unusually high stability in acidic environments — a property that has made it a frequent subject of preclinical investigation. Merit supplies it as a lyophilized research compound for research use only — not for human or veterinary use.
How does BPC-157 + TB-500 (Wolverine) work?
BPC-157 has been investigated in preclinical models for effects on angiogenesis (VEGF/VEGFR2 axis modulation), nitric oxide system regulation, growth hormone receptor expression, and dopaminergic / serotonergic system interactions. TB-500 functions primarily as an actin-sequestering protein involved in cell motility, organogenesis, and the regulation of actin polymerization in research models. Both peptides remain under active investigation; mechanisms described above reflect preclinical findings, not clinical conclusions. Mechanistic descriptions summarize published preclinical findings and are not clinical claims.
What is the half-life of BPC-157 + TB-500 (Wolverine)?
BPC-157: ~4 hr (preclinical, rat). TB-500: not well-characterized in the public literature. Values reflect preclinical or research-context reports, not clinical pharmacokinetics.
How is BPC-157 + TB-500 (Wolverine) reconstituted for research?
A lyophilized vial is reconstituted with bacteriostatic water; concentration equals vial mass divided by diluent volume. See the BPC-157 + TB-500 (Wolverine) reconstitution protocol for a step-by-step guide and a research calculator.
Is Merit BPC-157 + TB-500 (Wolverine) for human use?
No. It is sold strictly for research use only — not for human or veterinary use, and not for diagnostic or therapeutic use. Every lot ships with a certificate of analysis documenting ≥99% HPLC purity.
References
- Stable Gastric Pentadecapeptide BPC 157 in Honor of Professor Pavao Stuhli. Sikiric P, Seiwerth S, Rucman R, et al.. Current Pharmaceutical Design, 2018 · doi:10.2174/13816128113190990411
- Brain-gut axis and pentadecapeptide BPC 157: Theoretical and practical implications. Sikiric P, Rucman R, Turkovic B, et al.. Current Neuropharmacology, 2016 · PMID 27138887
- Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Expert Opinion on Biological Therapy, 2012 · PMID 22074294
For research use only. Not for human or veterinary use. Not FDA-approved. Reference information summarized from published literature — not medical or dosing advice.